Original ArticleA randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis
Under an Elsevier user license
open archive
Abbreviations
CF
cystic fibrosis
DMC
Data Monitoring Committee
FEV1
forced expiratory volume in 1 s
FVC
forced vital capacity
IV
intravenous
LTB4
leukotriene B4
PMNs
polymorphonuclear neutrophils.
Keywords
Cystic fibrosis
Clinical trial
Lung disease
Anti-inflammatory therapy
Leukotriene B4 receptor antagonist
Cited by (0)
- 1
These authors contributed equally to the work.
Copyright © 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.